Ajanta Pharma Limited — Board Meeting, 30-04-2025: Outcome of Board Meeting

Ajanta Pharma has announced a board meeting focusing on key financial results and updates. Q4 revenue stood at ₹1,170 Cr, reflecting an 11% YoY increase, while FY revenue reached ₹4,648 Cr, up 10%. EBITDA for Q4 was ₹297 Cr, with a margin of 25%. Profit after tax for Q4 grew 11% YoY to ₹225 Cr, totaling ₹920 Cr for FY 2025, a 13% increase. The board also approved a total shareholder payout of ₹700 Cr, including dividends and buybacks, indicating a robust 76% payout ratio.